In a patient with hypotension who is taking furosemide, losartan/hydrochlorothiazide, and diltiazem, which medication should be reduced first?

Reduce Diltiazem First

In a hypotensive patient taking furosemide, losartan/hydrochlorothiazide, and diltiazem, diltiazem should be reduced or discontinued first. Calcium channel blockers like diltiazem are the most likely culprit for acute hypotension in this scenario and can be safely reduced without compromising essential heart failure or hypertension management that depends on the other agents.

Rationale for Reducing Diltiazem

Diltiazem is a vasodilator that directly lowers blood pressure through peripheral vasodilation and can cause significant hypotension, particularly when combined with other antihypertensive agents 1. Calcium antagonists are not recommended in the management of acute heart failure 1, and diltiazem specifically can be discontinued without the same concerns about rebound effects or worsening heart failure that accompany diuretic or RAAS inhibitor withdrawal.

The 2022 AHA/ACC/HFSA guidelines emphasize that diuretics are essential for managing congestion and should not be discontinued in patients with fluid retention 2. Similarly, RAAS inhibitors (like losartan) are cornerstone guideline-directed medical therapy (GDMT) for heart failure and should be maintained even during periods of hemodynamic instability unless absolutely contraindicated 3.

Why Not the Other Medications?

Furosemide

Loop diuretics are critical for decongestion in heart failure patients 1, 4, 2. While high-dose diuretics can contribute to hypotension through volume depletion 1, patients with hypotension (SBP < 90 mmHg) are unlikely to respond to diuretic treatment alone 1. However, if the patient has evidence of ongoing congestion, stopping the diuretic would worsen their heart failure. The diuretic dose should only be reduced after confirming adequate decongestion and euvolemia.

Losartan/Hydrochlorothiazide

This combination provides dual benefit: RAAS blockade (essential GDMT for heart failure) and diuretic effect. The 2022 guidelines strongly recommend continuing RAAS inhibitors even during hospitalization for heart failure 3. Combined RAAS inhibitors with diuretics are effective and generally well tolerated 5. While the hydrochlorothiazide component contributes to blood pressure lowering, the losartan component is critical for long-term outcomes in heart failure.

Clinical Algorithm

1. Immediate action: Reduce or hold diltiazem
2. Assess volume status: Check for signs of congestion (JVP, edema, orthopnea)
3. If euvolemic: Consider reducing furosemide dose while maintaining diltiazem discontinuation
4. If still congested: Maintain furosemide, keep losartan/HCTZ at reduced dose if needed
5. Monitor closely: Daily weights, blood pressure, symptoms

Important Caveats

• If the patient has atrial fibrillation with rapid ventricular response, diltiazem may be serving a rate-control function. In this case, consider switching to a beta-blocker (which has mortality benefit in heart failure) rather than simply discontinuing rate control 2.

• Worsening kidney function during decongestion does not necessarily indicate true tubular injury 3. A modest rise in creatinine during effective diuresis with clinical improvement is acceptable and should not prompt discontinuation of GDMT 3.

• The combination of losartan with hydrochlorothiazide has demonstrated additive blood pressure lowering with good tolerability 6, 7, but in the setting of hypotension, the thiazide component could be separated and reduced while maintaining the ARB.

• Avoid combining multiple RAAS inhibitors (ACE inhibitor + ARB), as this increases risk without additional benefit 8, 9.